Literature DB >> 25230936

Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays.

Teddy Kamata1, Mohan Natesan1, Kelly Warfield2, M Javad Aman2, Robert G Ulrich3.   

Abstract

Infectious hemorrhagic fevers caused by the Marburg and Ebola filoviruses result in human mortality rates of up to 90%, and there are no effective vaccines or therapeutics available for clinical use. The highly infectious and lethal nature of these viruses highlights the need for reliable and sensitive diagnostic methods. We assembled a protein microarray displaying nucleoprotein (NP), virion protein 40 (VP40), and glycoprotein (GP) antigens from isolates representing the six species of filoviruses for use as a surveillance and diagnostic platform. Using the microarrays, we examined serum antibody responses of rhesus macaques vaccinated with trivalent (GP, NP, and VP40) virus-like particles (VLP) prior to infection with the Marburg virus (MARV) (i.e., Marburg marburgvirus) or the Zaire virus (ZEBOV) (i.e., Zaire ebolavirus). The microarray-based assay detected a significant increase in antigen-specific IgG resulting from immunization, while a greater level of antibody responses resulted from challenge of the vaccinated animals with ZEBOV or MARV. Further, while antibody cross-reactivities were observed among NPs and VP40s of Ebola viruses, antibody recognition of GPs was very specific. The performance of mucin-like domain fragments of GP (GP mucin) expressed in Escherichia coli was compared to that of GP ectodomains produced in eukaryotic cells. Based on results with ZEBOV and MARV proteins, antibody recognition of GP mucins that were deficient in posttranslational modifications was comparable to that of the eukaryotic cell-expressed GP ectodomains in assay performance. We conclude that the described protein microarray may translate into a sensitive assay for diagnosis and serological surveillance of infections caused by multiple species of filoviruses.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25230936      PMCID: PMC4248775          DOI: 10.1128/CVI.00484-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  51 in total

1.  Interactions of Marburg virus nucleocapsid proteins.

Authors:  S Becker; C Rinne; U Hofsäss; H D Klenk; E Mühlberger
Journal:  Virology       Date:  1998-09-30       Impact factor: 3.616

2.  Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.

Authors:  E Mühlberger; B Lötfering; H D Klenk; S Becker
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  Antibody recognition of the dengue virus proteome and implications for development of vaccines.

Authors:  Stefan Fernandez; Emily D Cisney; Alexander P Tikhonov; Barry Schweitzer; Robert J Putnak; Monika Simmons; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

Review 4.  Marburg and Ebola viruses.

Authors:  H Feldmann; H D Klenk
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

Review 5.  Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa.

Authors:  E M Leroy; J-P Gonzalez; S Baize
Journal:  Clin Microbiol Infect       Date:  2011-07       Impact factor: 8.067

6.  GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases.

Authors:  V E Volchkov; S Becker; V A Volchkova; V A Ternovoj; A N Kotov; S V Netesov; H D Klenk
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

Review 7.  Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa.

Authors:  Yokouide Allaranga; Mamadou Lamine Kone; Pierre Formenty; Francois Libama; Paul Boumandouki; Celia J I Woodfill; Idrissa Sow; Sambe Duale; Wondimagegnehu Alemu; Adamou Yada
Journal:  East Afr J Public Health       Date:  2010-03

8.  Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus.

Authors:  A Sanchez; M P Kiley; B P Holloway; D D Auperin
Journal:  Virus Res       Date:  1993-09       Impact factor: 3.303

9.  Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.

Authors:  A Sanchez; Z Y Yang; L Xu; G J Nabel; T Crews; C J Peters
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus.

Authors:  Adam Macneil; Zachary Reed; Pierre E Rollin
Journal:  PLoS Negl Trop Dis       Date:  2011-06-07
View more
  9 in total

Review 1.  Strategies in Ebola virus disease (EVD) diagnostics at the point of care.

Authors:  Chad T Coarsey; Nwadiuto Esiobu; Ramswamy Narayanan; Mirjana Pavlovic; Hadi Shafiee; Waseem Asghar
Journal:  Crit Rev Microbiol       Date:  2017-04-25       Impact factor: 7.624

Review 2.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

3.  Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.

Authors:  Mohan Natesan; Stig M Jensen; Sarah L Keasey; Teddy Kamata; Ana I Kuehne; Spencer W Stonier; Julius Julian Lutwama; Leslie Lobel; John M Dye; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

Review 4.  Ebolavirus comparative genomics.

Authors:  Se-Ran Jun; Michael R Leuze; Intawat Nookaew; Edward C Uberbacher; Miriam Land; Qian Zhang; Visanu Wanchai; Juanjuan Chai; Morten Nielsen; Thomas Trolle; Ole Lund; Gregory S Buzard; Thomas D Pedersen; Trudy M Wassenaar; David W Ussery
Journal:  FEMS Microbiol Rev       Date:  2015-07-14       Impact factor: 16.408

Review 5.  Viral glycoproteins: biological role and application in diagnosis.

Authors:  Nilotpal Banerjee; Sumi Mukhopadhyay
Journal:  Virusdisease       Date:  2016-01-18

6.  Human Antibody Responses to Emerging Mayaro Virus and Cocirculating Alphavirus Infections Examined by Using Structural Proteins from Nine New and Old World Lineages.

Authors:  Jessica L Smith; Christine L Pugh; Emily D Cisney; Sarah L Keasey; Carolina Guevara; Julia S Ampuero; Guillermo Comach; Doris Gomez; Margarita Ochoa-Diaz; Robert D Hontz; Robert G Ulrich
Journal:  mSphere       Date:  2018-03-21       Impact factor: 4.389

7.  A Smartphone-Based Rapid Telemonitoring System for Ebola and Marburg Disease Surveillance.

Authors:  Mohan Natesan; Sz-Wei Wu; Chieh-I Chen; Stig M R Jensen; Neven Karlovac; Beverly K Dyas; Onur Mudanyali; Robert G Ulrich
Journal:  ACS Sens       Date:  2018-12-28       Impact factor: 7.711

8.  Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection.

Authors:  Sizun Jiang; Nilanjan Mukherjee; Richard S Bennett; Han Chen; James Logue; Bonnie Dighero-Kemp; Jonathan R Kurtz; Ricky Adams; Darci Phillips; Christian M Schürch; Yury Goltsev; John W Hickey; Erin F McCaffrey; Alea Delmastro; Pauline Chu; J Rachel Reader; Rebekah I Keesler; José A Galván; Inti Zlobec; Koen K A Van Rompay; David X Liu; Lisa E Hensley; Garry P Nolan; David R McIlwain
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

9.  Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples.

Authors:  Rebecca Surtees; Daniel Stern; Katharina Ahrens; Nicole Kromarek; Angelika Lander; Petra Kreher; Sabrina Weiss; Roger Hewson; Emma K Punch; John N Barr; Peter T Witkowski; Emmanuel Couacy-Hymann; Andrea Marzi; Brigitte G Dorner; Andreas Kurth
Journal:  PLoS Negl Trop Dis       Date:  2020-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.